Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GSK PLC closed 14.69% below its 52-week high of £17.67, which the company reached on May 31st.

Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Analysts at Berenberg downgraded drugmaker GSK from 'buy' to 'hold' on Tuesday as it awaited upcoming product launches.

With that, Theravance expects its lifetime value from the inhaler to come out to $1.52 billion. The drug stems from a 2002 ...

Research conducted at Uskudar University (Istanbul, Turkey) explored the neuroprotective potential of ethanolic extracts of ...

Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase ...

Johnson & Johnson (JNJ) posts Phase 3 trial win for Akkega plus prednisone in metastatic castration-sensitive prostate cancer ...

GSK plc GSK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval of its ...

CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.